- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05278364
Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor
A Phase I/II, Open-Label, Single-arm, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of SY-5007 in Patients With RET-altered Advanced Solid Tumor.
Study Overview
Status
Intervention / Treatment
Detailed Description
The study consists of 2 parts:
Part 1: Dose-escalation and dose-expansion in patients with RET Fusion-Positive NSCLC or RET-mutated MTC or other RET-altered advanced solid tumor. Dose-escalation study phase is designed to determine the DLTs (Dose-limiting toxicity) and recommended phase II dose (RP2D) and to characterize the safety, tolerability, and pharmacokinetics (PK) profile of SY-5007. Dose-expansion study phase is designed to evaluate the antitumor activity (ORR, DCR and DoR) of SY-5007 in patients.
Part 2: Phase II study to evaluate the antitumor efficacy of SY-5007. Patients with advanced RET Fusion-Positive NSCLC will be enrolled in this phase. SY-5007 will be administered orally 160mg twice daily in a 28-day cycle. This phase is designed to determine the antitumor activity (ORR, DCR, DoR, PFS and OS), safety, and PK of SY-5007.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200433
- Recruiting
- Shanghai Pulmonary Hospital
-
Contact:
- Caicun Zhou, PHD
- Phone Number: 13301825532
- Email: caicunzhoudr@163.com
-
-
Tianjin
-
Tianjin, Tianjin, China, 300000
- Recruiting
- Tianjin People's Hospital
-
Contact:
- Ming Gao, PhD
- Email: Headandneck2008@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
-
For Phase I:
- Male or female, at least 18 years of age.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
- Estimated life expectancy >12 weeks.
- Patients must have at least one assessable lesion in dose-escalation part and one measurable lesion in dose-expansion part per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Dose-escalation Part: patients must have histological or cytological confirmed advanced solid tumours with RET alteration (fusion or mutation) and have progressed after standard therapy, or no standard or available curative therapy exists.
Dose-expansion Part: Patients with advanced tumor must have histological or cytological confirmed RET alteration, including NSCLC patients with RET-fusion or MTC patients with RET-mutation or other patients with RET alteration, and either have progressed after standard therapy or no standard/ available curative therapy exists.
Patients must have adequate organ function as defined in the below:
Hepatic function:
Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 3 times the upper limit of normal (ULN) if no hepatic metastases are present, or otherwise ≤ 5 times ULN, Total serum bilirubin (TBIL) ≤ 1.5 times ULN.
Bone marrow function (No blood transfusion or haematopoietic stimulating factor treatment within 10 days prior to testing):
Absolute neutrophil count (ANC) ≥ 1.5 x 10⁹/L; Platelets (PLT) count ≥ 75 x 10⁹/L; Hemoglobin (Hb) ≥ 85 g/L.
Renal function:
Creatinine clearance ≥ 50 mL/min.
Coagulation function:
Prothrombin time (PT) or International Normalized Ratio (INR) ≤ 1.5 times ULN.
Serum lipid:
Cholesterol ≤ 500mg/dL(12.92mmol/L).
- Female patients with reproductive potential must have a negative serum pregnancy test within 7 days prior to the first dose, male and female patients of childbearing potential must be willing to completely abstain or agree to use an appropriate method of contraception during the entire study duration and for at least 3 months after the last dose of study medication.
Willingness and ability to give informed consent and follow protocol procedures, and comply with follow-up visit requirements.
For Phase II: As for phase I with the following modifications:
- Participants must have histological or cytological confirmed locally advanced or metastatic RET Fusion-Positive NSCLC, have progressed following platinum-based chemotherapy and/or PD-1/PD-L1 immunotherapy, or have not received prior systemic therapy, or in the opinion of the Investigator, they would be unlikely to tolerate or derive significant clinical benefit from appropriate standard of care therapy, or they declined standard therapy.
The participants' tumor tissue or blood sample test results meet 1 of the following 2 criteria:
- Previous tumor tissue or blood sample confirmed positive for RET fusion by local laboratory.
- If no previous positive RET fusion test report is available, a compliant tumor tissue or blood sample must be tested at a central laboratory designated by the sponsor, using a second-generation sequencing (NGS)-based assay, and confirmed as positive for RET fusion.
Exclusion Criteria:
- Dose-expansion Part: Patient's cancer has a known primary driver alteration other than RET. e.g. EGFR, ALK, ROS1, KRAS, etc.
- Dose-expansion Part: Patients previously treated with a selective RET inhibitor.
Patients received systemic antitumor therapy, including chemotherapy, radiotherapy, biologic therapy, endocrine therapy, or immunotherapy within 3 weeks prior to the first dose, except for the following:
Nitrosoureas or mitomycin C within 6 weeks; Oral fluorouracils and small molecule drugs within 2 weeks or within 5 half-life periods of the drug (whichever is longer); Antitumour traditional Chinese medicine within 2 weeks.
- Patients received other unlisted clinical trial drugs or treatments within 4 weeks prior to the first dose.
- Patients underwent major organ surgery (excluding puncture biopsy) or had significant trauma within 4 weeks prior to the first dose.
- Adverse effects of previous anti-tumor therapy have not recovered to CTCAE 5.0 grade rating of ≤ grade 1 (except for toxicity judged by the investigator be of no safety risk, such as alopecia, grade 2 peripheral neurotoxicity, etc.)
- Patients have symptomatic central nervous system (CNS) metastases, meningeal metastases, or a primary CNS tumor that is associated with progressive neurological symptoms.
- Patients with active uncontrolled systemic bacterial, viral, or fungal infection despite optimal treatment (chronic disease screening not required).
- Active hepatitis (Hepatitis B: HBsAg-positive and HBV-DNA ≥ 2000 IU/ mL; Hepatitis B: HCV antibody-positive and HCV-RNA ≥ 1000 IU/ml), HIV antibody-positive; Active syphilis.
Patients have a history of severe cardiovascular disease, including but not limited to:
Severe cardiac rhythm or conduction abnormalities, e.g. ventricular arrhythmia requiring clinical intervention, II-III degree atrioventricular block, etc.
Mean QT interval corrected using Fridericia's formula (QTcF)> 480ms at rest. Acute coronary syndrome, congestive heart failure, aortic coarctation, stroke or other grade 3 or higher cardiovascular or cerebrovascular events within 6 months prior to the first dose.
New York Heart Association (NYHA) ≥ class II heart failure or left ventricular ejection fraction (LVEF) < 50%.
Hypertension remains uncontrolled after aggressive antihypertensive therapy.
- Patients have been treated with any CYP3A inhibitors or inducers within 14 days prior to the first dose.
- Patients with malignancies other than tumors treated in this study (except: malignancies that are cured and have not recurred within 3 years prior to study entry; completely resected basal cell and squamous cell skin cancer; completely resected carcinoma in situ of any type).
Patients are unable to swallow the drug orally, or has a condition that seriously affects gastrointestinal absorption in the judgment of the investigator.
For Phase II: As for phase I with the following modifications:
- Patients received any selective RET inhibitor (including marketed drugs such as selpercatinib, pralsetinib, and unmarketed experimental drugs).
- Patients have a history of hypersensitivity to any component or excipient of SY-5007 capsule.
- Patients participated in another clinical study within 4 weeks prior to the first dose or is scheduled to participate in another clinical study during the study period.
- Pregnant or breastfeeding female patients.
- Other conditions deemed by the investigator to be inappropriate for participation in this clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose-escalation and Dose-expansion
Dose-escalation Phase: Multiple doses of SY-5007 for oral administration. Dose Expansion Phase: RP2D of SY-5007 as determined during Dose Escalation. |
a RET selective Inhibitor
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I: Determine the dose-limiting toxicities (DLT) during the first 28-day cycle of SY-5007 treatment
Time Frame: Dose-escalation Cycle 1 (each cycle is 28 days)
|
Maximum Tolerated Dose (MTD) and/or recommended phase 2 dose (RP2D) in Cycle 1
|
Dose-escalation Cycle 1 (each cycle is 28 days)
|
Phase I: Number of patients with adverse events and serious adverse events
Time Frame: Up to 24 months
|
Characterization of the safety and tolerability
|
Up to 24 months
|
Phase II: Overall Response Rate (ORR) as assessed by RECIST 1.1 criteria
Time Frame: Up to 24 months
|
Anti-tumor activity of SY-5007
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I: Overall Response Rate (ORR) as assessed by RECIST 1.1 criteriaOverall Response Rate (ORR) as assessed by RECIST 1.1 criteria
Time Frame: Up to 24 months
|
Preliminary anti-tumor activity of SY-5007
|
Up to 24 months
|
Phase I & II: Disease control rate (DCR) as assessed by RECIST 1.1 criteria
Time Frame: Up to 24 months
|
Preliminary anti-tumor activity of SY-5007
|
Up to 24 months
|
Phase I & II: Duration of response (DOR)
Time Frame: Up to 24 months
|
Preliminary anti-tumor activity of SY-5007
|
Up to 24 months
|
Phase I & II: Progression Free Survival (PFS)
Time Frame: Up to 24 months
|
Preliminary anti-tumor activity of SY-5007
|
Up to 24 months
|
Phase I & II: Overall survival (OS)
Time Frame: Up to 24 months
|
Anti-tumor activity of SY-5007
|
Up to 24 months
|
Phase I & II: Percentage of Participants with any Serious Adverse Events (SAEs)
Time Frame: Up to 24 months
|
Characterization of the safety and tolerability
|
Up to 24 months
|
Phase I & II: Pharmacokinetic Parameters Including Maximum Plasma Drug Concentration (Cmax)
Time Frame: Protocol-defined time points during Cycles 1 and 2 of treatment, up to approximately 2 months per subject
|
Cmax of SY-5007
|
Protocol-defined time points during Cycles 1 and 2 of treatment, up to approximately 2 months per subject
|
Phase I & II: Pharmacokinetic Parameters Including time to maximum plasma concentration (Tmax) of SY-5007
Time Frame: Protocol-defined time points during Cycles 1 and 2 of treatment, up to approximately 2 months per subject
|
Tmax of SY-5007
|
Protocol-defined time points during Cycles 1 and 2 of treatment, up to approximately 2 months per subject
|
Phase I & II: Pharmacokinetic Parameters Including Area Under the Plasma Concentration-Time Curve of SY-5007 (AUC)
Time Frame: Protocol-defined time points during Cycles 1 and 2 of treatment, up to approximately 2 months per subject
|
AUC of SY-5007
|
Protocol-defined time points during Cycles 1 and 2 of treatment, up to approximately 2 months per subject
|
Phase I & II: Pharmacokinetic Parameters Including Terminal Elimination Half-life (t1/2) of SY-5007
Time Frame: Protocol-defined time points during Cycles 1 and 2 of treatment, up to approximately 2 months per subject
|
plasma terminal phase disposition half-life of SY-5007
|
Protocol-defined time points during Cycles 1 and 2 of treatment, up to approximately 2 months per subject
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- SY-5007-I
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
Clinical Trials on SY-5007
-
Shouyao Holdings (Beijing) Co. LTDRecruitingNon-Small Cell Lung CancerChina
-
Shouyao Holdings (Beijing) Co. LTDNot yet recruiting
-
Shouyao Holdings (Beijing) Co. LTDNot yet recruiting
-
Shouyao Holdings (Beijing) Co. LTDRecruitingAdvanced Solid TumorChina
-
Shouyao Holdings (Beijing) Co. LTDRecruitingAdvanced Solid TumorChina
-
Shouyao Holdings (Beijing) Co. LTDRecruiting
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.CompletedType 2 Diabetes MellitusChina
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.Completed
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.Suspended
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.Completed